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Background: The International Prognostic Index and its modifications are used to estimate prognosis in non-Hodgkin lymphoma. 
However, the outcome is often different in patients with similar index scores. Aim: The aim of this study was to elaborate a prognostic 
model for patients with mature B-cell non-Hodgkin lymphoma using a combination of predictive markers. Material and methods: The 
study included 45 patients with mature B-cell non-Hodgkin lymphoma. Before the administration of treatment, clinical and laboratory 
parameters were measured. After the 35-month follow-up period, overall survival was studied in relation to the data obtained at initial 
examination. Results: We revealed nine adverse predictive markers for overall survival of enrolled patients: Eastern Cooperative Oncology 
Group (ECOG) performance status >1; erythrocyte sedimentation rate >30 mm/h; levels of hemoglobin <120 g/L, fibrinogen ≥6 g/L, 
interleukin-6 ≥2 pg/mL, tumor necrosis factor ≥1.45 pg/mL, soluble fibrin monomer complexes >4 mg/dL, high-density lipoprotein 
cholesterol <1.03 mmol/L in men, and <1.29 mmol/L in women; and short activated partial thromboplastin time. A prognostic model for 
the estimation of the risk of death within the ensuing 1.5–2 years in patients with non-Hodgkin lymphoma was constructed. 
Conclusion: Markers of inflammation, anemia, hypercoagulability, dyslipidemia, and poor ECOG status are associated with worse survival 
in patients with mature B-cell non-Hodgkin lymphoma.
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All rights reserved.
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Introduction
Estimation of disease prognosis is very important, especially in 
malignancies, which helps to determine viable treatment strategies. 
For this purpose, the International Prognostic Index (IPI), the Mantle 
Cell Lymphoma IPI, the Follicular Lymphoma IPI, and other indexes 
are used in some types of non-Hodgkin lymphoma (NHL). However, 
in patients with identical prognostic indexes, different disease courses 
are often observed [1]. On the other hand, we do not have universal 
prognostic factors for all types of NHL, although there are different data 
in the literature about new predictive markers in some concrete NHL 
cases [2, 3]. It is known that systemic inflammation, hypercoagulability, 
and dyslipidemia play a vague role in pathogenesis, progression, and 
complications of NHL [4–7]. The aims of our study were to estimate the 
risk of death of patients with mature B-cell NHL in relation to various 
clinical, proinflammatory, hemostatic, and biochemical parameters 
and thereafter construct a prognostic model using a combination of 
predictive markers.
Material and Methods
The study involved 45 patients with mature B-cell NHL: 26 men and 
19 women aged 26–80 years (the median age was 60 years; the 
interquartile interval was 53–65 years). Criteria for exclusion from the 
study were the following: infectious and other inflammatory diseases, 
thrombosis and thromboembolism during the previous 3 months, 
treatment with anticoagulants, and surgical intervention or radiotherapy 
for the previous 2 weeks.
The majority of patients had diffuse large B-cell lymphoma – 23 (51.1%); 
others were diagnosed with the following: small lymphocytic lymphoma 
– 2 (4.4%), marginal zone lymphoma – 3 (6.7%), mantle cell lymphoma 
– 2 (4.4%), follicular lymphoma – 2 (4.4%), lymphoplasmocytic 
lymphoma – 4 (8.9%) and chronic lymphocytic leukemia (CLL) – 9 
(20.0%) patients. The following Ann Arbor stages of the disease were 
identified in 30 patients with NHL (after the exclusion of 4 patients 
with lymphoplasmocytic lymphoma and 2 patients with relapse): stage 
I – 4 (13.3%) patients, stage II – 8 (26.7%) patients, stage III – 4 
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(13.3%) patients, and stage IV – 14 (46.7%) patients. Among the 9 
patients with CLL, according to the Rai staging system, stage II was 
established in 1 (11.1%) patient, stage III in 3 (33.3%) patients, and 
stage IV in 5 (55.6%) patients.
Clinical and laboratory studies were performed before the onset 
of first-line chemotherapy in 19 (42.2%) patients, before the next 
cycle of first-line chemotherapy regimen in 15 (33.3%) patients 
and before the next cycle of second-line chemotherapy regimen 
in 11 (24.4%) patients. Laboratory examination of the enrolled 
patients was carried out at the Institute of Blood Pathology and 
Transfusion Medicine of the NAMS of Ukraine, a specialized clinical 
and diagnostic laboratory. Serum levels of the proinflammatory 
cytokines, interleukin-6 (IL-6) and tumor necrosis factor (TNF), were 
measured using an enzyme-linked immunosorbent assay with the 
A-8768  “Interleukin-6-ELISA-BEST” and A-8756 “α-TNF-ELISA-
BEST” reagent kits (VECTOR-BEST, Ukraine), respectively. The 
following blood coagulation parameters were estimated: plasma 
fibrinogen levels (Clauss method), prothrombin time, prothrombin 
index, and activated partial thromboplastin time (APTT) by the 
chronometric method using the Coag-Chrom 3003 coagulometer 
(Bio-Ksel, Poland); levels of soluble fibrin monomer complexes 
(SFMCs) by the ortho-phenanthroline test (Technology-Standard, 
Russia); and levels of highly sensitive d-dimer by immunoassay 
using the reagent kit D-9120 "D-dimer-ELISA-BEST" (VECTOR-
BEST, Ukraine). Elevated levels of SFMCs (a marker of thrombin 
generation; >4 mg/dL), d-dimer (a product of fibrin degradation 
during fibrinolysis; >250 mg/L), and shortened APTT were 
considered as hypercoagulability [8, 9]. In 11 (24.4%) patients 
with d-dimer levels >500 mg/L, Doppler ultrasound of the lower 
extremities was performed, which ruled out venous thrombosis 
in all of them. Parameters of lipid metabolism, such as levels of 
triglycerides, total cholesterol, high-density lipoprotein cholesterol 
(HDL-Ch), and low-density lipoprotein cholesterol, were measured 
using standard enzymatic methods.
The overall functional state of patients, as a quantitative reflection of 
their state of health and daily activity, was evaluated using a system 
developed by the Eastern Cooperative Oncology Group (ECOG). 
The ECOG performance status defines scores ranging from “0” to 
“5”, where score 0 means total health and score 5 indicates death.
Statistical analysis
In order to identify the predictive markers, we performed analyses 
of overall survival (OS) using the Kaplan–Meier method. OS was 
defined as the time from study enrollment until death from any 
cause. Cox’s F-test was used to detect the relationship between 
the studied parameters and OS. Cumulative 1-year and 2-year 
survival was determined by the life table method. Subsequently, 
a multivariate Cox proportional-hazards regression model was 
used, with OS as the dependent variable. To construct a model that 
predicts survival, the Wald method was used for calculation of the 
diagnostic coefficients of every factor. Chi-squared test and Cox’s 
F-test were used to compare the OS in different risk groups. In order 
to find correlations, the Kendall tau (τ) test was used. P-values had 
to be <0.05 to indicate statistical significance. For statistical analysis 
of the results, the software package “Statistica for Windows 6.0” 
(Statsoft, USA) was used.
Results
After enrollment in the investigation, patients were treated with 
aggressive chemotherapy regimens in 26 (57.8%) cases; among 
these, 22 cases were treated with CHOP-like regimens: CHOP 
(cyclophosphamide, doxorubicin, vincristine, and prednisone), 
R-CHOP (with addition of rituximab), and R-CHOEP (with addition 
of rituximab and etoposide) and four cases with other regimens: 
R-DHAP (rituximab, dexamethasone, high-dose cytarabine, and 
cisplatin), Hyper-CVAD (course A: cyclophosphamide, vincristine, 
doxorubicin, and dexamethasone; course B: methotrexate and 
cytarabine), and four cases with other  regimens: R-DHAP 
(rituximab, dexamethasone, high-dose cytarabine, and cisplatin), 
Hyper-CVAD (course A: cyclophosphamide, vincristine, doxorubicin, 
and dexamethasone; course B: methotrexate and cytarabine), and 
gemcitabine regimens). A total of 19 (42.2%) patients received less-
aggressive regimens, such as CVP (cyclophosphamide, vincristine, 
and prednisone), R-CVP (with addition of rituximab), FC (fludarabine 
and cyclophosphamide), R-FC (with addition of rituximab), 
R-DC (rituximab, dexamethasone, and cyclophosphamide), BR 
(bendamustine and rituximab), and rituximab or chlorambucil alone.
During the 35-month follow-up period (the median was 23 months), 
response to treatment was achieved in 26 (57.8%) patients, 
including a complete remission in 21 (46.7%) patients (with further 
development of relapse in 4 of them) and a partial response in 5 
(11.1%) patients. The disease was stable in 2 (4.4%) patients, and 
it progressed in 1 (2.2%) patient; meanwhile, 16 (35.6%) patients 
died.
We estimated the OS of patients in relation to all the studied 
parameters, which were recorded at the time of initial examination. 
Significant relations were established with nine clinical and 
laboratory markers, such as ECOG score, erythrocyte sedimentation 
rate (ESR), APTT, and levels of hemoglobin, IL-6, TNF, fibrinogen, 
SFMCs, and HDL-Ch.
The survival of patients was analyzed in relation to their functional 
state, according to the ECOG scale. The patients’ ECOG scores 
were assigned as follows: Grade 0: seven (15.6%) patients; Grade 
1:27 (60.0%) patients; Grade 2: three (6.7%) patients; Grade 3: five 
(11.1%) patients; and Grade 4: three (6.7%) patients. ECOG grade 
>1 was found in 11 (24.4%) patients. It indicated low functional 
capacity and was associated with significantly worse OS. Over the 
35 months of follow-up, the cumulative proportion surviving among 
the 11 patients with ECOG >1 was 36.4%, which was significantly 
lower than the cumulative proportion surviving (73.3%) among the 
34 patients with ECOG grades 0–1 (p = 0.010).
On the basis of the analysis of associations between the OS of 
patients with NHL and markers of anemia, systemic inflammation, 
hypercoagulability, and dyslipidemia, laboratory predictors of death 
were established (Tab. I).
Anemia with hemoglobin levels <120 g/L was detected in 22 
(48.9%) patients. Among these patients, anemia was mild in 15 
(68.2%) patients, moderate in six (27.3%) patients, and severe in 
one (4.5%) patient. The survival of patients in relation to the level of 
hemoglobin was estimated. According to the cumulative proportion 
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surviving for 1 year and 2 years, OS was significantly worse in 
patients with anemia (Tab. I). A negative correlation was found 
between hemoglobin levels and ECOG scores in the examined 
patients (Tab. II), which reflects the relationships between predictive 
biomarkers. We also found a weak negative correlation between 
hemoglobin and IL-6 levels (Tab. II).
A decrease in OS was associated with ESR >30 mm/h before the 
onset of treatment (Tab. I). This value indicates B symptoms of 
tumor, intoxication, and systemic inflammatory response and was 
observed in 11 (28.2%) out of the 39 examined patients.
We evaluated the OS of patients in relation to serum levels of 
IL-6. Using Wald’s sequential analysis, we determined that the 
threshold level of IL-6 that predicted better survival was 2.0 pg/mL. 
Comparing the OS in subgroups of patients with IL-6 levels either 
more than or less than 2.0 pg/mL (28 and 17 patients, respectively), 
the cumulative proportion of OS was found to be significantly lower 
in the first subgroup (Tab. I).
We estimated the OS of patients with NHL in relation to the TNF 
levels. A subgroup of 10 (22.2%) patients had levels of TNF ≥1.45 
pg/mL, and in the remaining 35 (77.8%) patients, the serum TNF 
level was undetectable. The OS of patients in the first subgroup 
was significantly worse compared to patients in the second one 
(Tab. I).
Reduction in OS was associated with levels of fibrinogen ≥6 g/L. 
This level was established empirically and was close to the upper 
interquartile value of 5.62 g/L. In eight (17.8%) patients with such 
levels, the cumulative proportions of OS for 12 and 24 months were 
significantly lower than in the subgroup of 37 (82.2%) patients with 
fibrinogen levels <6 g/L (Tab. I).
In the examined patients, features of systemic inflammation 
were associated with hypercoagulability, which was confirmed by 
significant direct correlations between levels of TNF and d-dimer, 
as well as between ESR and levels of IL-6, on the one hand, and 
SFMC levels, on the other hand (Tab. II).
Table I. Overall survival of patients with non-Hodgkin lymphoma depending on levels of laboratory markers
Markers Cumulative proportion surviving for 12 months, % Cumulative proportion surviving for 24 months, % Cox’s F-test, р
Hemoglobin <120 g/L 63.7 42.9 0.030
Hemoglobin ≥120 g/L 73.5 64.4
ESR >30 mm/h 45.8 26.0 0.042
ESR ≤30 mm/h 78.9 67.7
IL-6 ≥2.0 pg/mL 62.6 45.0 0.002
IL-6 <2.0 pg/mL 80.7 70.0
TNF ≥1.45 pg/mL 45.8 22.0 0.040
TNF undetectable 78.7 66.9
Fibrinogen ≥6 g/L 45.0 0 0.010
Fibrinogen <6 g/L 77.1 68.8
SFMC >4 m/dL 47.7 34.3 0.002
SFMC ≤4 mg/dL 87.7 73.3
APTT <30 s 57.0 31.0 0.042
APTT ≥30 s 78.5 68.3
HDL-Ch low 53.0 39.1 0.033
HDL-Ch normal* 83.5 68.1
APTT – activated partial thromboplastin time; ESR – erythrocyte sedimentation rate; HDL-Ch – high-density lipoprotein cholesterol; IL-6 – interleukin-6; SFMC – soluble fibrin mono-
mer complex; TNF – tumor necrosis factor. * HDL-Ch levels ≥1.03 mmol/L in men and ≥1.29 mmol/L in women.
Table II. Correlations between the studied parameters in patients with non-Hodgkin lymphoma (Kendall’s tau test)







HDL-Ch ECOG scores 0.044
Hemoglobin ECOG scores 0.008
Hemoglobin IL-6 0.053
APTT – activated partial thromboplastin time; ECOG – Eastern Cooperative Oncology Group; ESR – erythrocyte sedimentation rate; HDL-Ch – high-density lipoprotein cholesterol; 
IL-6 – interleukin-6; SFMC – soluble fibrin monomer complex; TNF – tumor necrosis factor. * In women.
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In 19 (42.2%) patients, there were increased levels of SFMCs 
(>4 mg/dL). It was found that the OS of these patients was worse 
compared to the OS of patients with levels of SFMCs ≤4 mg/dL, as 
evidenced by the significantly lower cumulative proportion surviving 
(Tab. I).
APTT values shorter than the reference value of 30 s were noted 
in 15 (33.3%) patients. An inverse correlation between levels of 
d-dimer and APTT was found (Tab. II). This correlation confirms that 
short APTT can be considered as a marker of hypercoagulability, 
since, according to the literature, it is associated with increased 
thrombin generation [8]. We found that shortened APTT was a 
predictor of worse outcome for patients with NHL because the 
cumulative proportion of OS was significantly lower among them 
in comparison to the OS of patients in whom the APTT was within 
reference values (Tab. I).
HDL-Ch level <1.03 mmol/L in men and <1.29 mmol/L in women is 
considered to be low according to the definition of the International 
Federation of Diabetes. Such a low concentration of HDL-Ch was 
detected in 18 (40.0%) patients: 8 females and 10 males. Low 
levels of HDL-Ch were associated with worse OS in the examined 
patients (Tab. I). Levels of HDL-Ch correlated inversely with d-dimer 
levels in women, as well as TNF levels and ECOG scores in both 
genders (Tab. II).
Thus, estimation of Kaplan–Mayer survival curves over the 
maximum 35-month follow-up period allowed the detection of 
unfavorable prognostic factors for OS in patients with NHL, 
including the following: hypercoagulability markers, such as SFMC 
levels >4 mg/dL and APTT shorter than 30 s; laboratory features 
of systemic inflammation, such as levels of fibrinogen ≥6 g/L, IL-6 
≥2 pg/mL, TNF ≥1.45 pg/mL, ESR >30 mm/h, and anemia with 
hemoglobin levels <20 g/L; features of dyslipidemia, such as low 
HDL-Ch levels <1.03 mmol/L in men and <1.29 mmol/L in women; 
and poor performance status with ECOG scores >1.
Subsequently, we analyzed these nine predictive markers in a 
multivariate Cox proportional‐hazards regression model. We 
determined that the independent predictors of OS were SFMC level 
>4 mg/dL, IL-6 level ≥2 pg/mL, and ECOG status score >1 (p = 
0.0001).
Table III. The prognostic model for determination of overall survival of patients with non-Hodgkin lymphoma
No Predictors Death before 18 months (n)
Censored after 18 months 
(n) Score Corrected score Kullback information quantity
1 ECOG grade 0–1 9 23 –1.966 –2 0.322
ECOG grade >1 7 3 5.788 6 0.966
=1.288
2 Hemoglobin ≥120 g/L 5 16 –3.113 –3 0.491
Hemoglobin <120 g/L 11 9 2.810 3 0.491
=0.982
3 ESR ≤30 mm/h 7 19 –1.859 –2 0.288
ESR >30 mm/h 6 4 4.239 4 0.575
=0.863
4 IL-6 <2 pg/mL 2 14 –6.690 –7 1.604
IL-6 ≥2 pg/mL 14 10 3.222 3 0.688
=2.292
5 TNF = 0 pg/mL 10 23 –1.509 –1.5 0.195
TNF >0 pg/mL 6 3 5.119 5 0.649
=0.844
6 Fibrinogen <6 g/L 10 26 –2.041 –2 0.375
Fibrinogen ≥6 g/L 6 0 3 0.563
=0.938
7 SFMC ≤4 mg/dL 4 19 –4.078 –4 0.890
SFMC >4 mg/dL 10 7 4.237 4.5 1.001
=1.891
8 APTT ≥30 s 8 16 –1.249 –1 0.083
APTT <30 s 8 8 1.761 2 0.167
=0.250
9 HDL-Ch normal* 7 18 –3.590 –3.5 0.984
HDL-Ch low 9 8 1.023 1 0.059
=1.043
APTT – activated partial thromboplastin time; ECOG – Eastern Cooperative Oncology Group; ESR – erythrocyte sedimentation rate; HDL-Ch – high-density lipoprotein cholesterol; 
IL-6 – interleukin-6; SFMC – soluble fibrin monomer complex; TNF – tumor necrosis factor. 
* HDL-Ch levels ≥1.03 mmol/L in men and ≥1.29 mmol/L in women.
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Based on these results, a predictive model was developed for 
estimating the risk of death using the Wald method. To determine 
the diagnostic coefficients of every factor, taking into consideration 
that all deaths occurred within a period of 18 months, we compared 
the clinical and laboratory parameters of all dying patients with the 
same parameters in patients censored after 18 months (Tab. III). 
Scores from the proposed nine markers are summarized for each 
patient. The result is defined as a risk of death within 1.5–2 years, 
which is evaluated and divided into the following risk categories 
according to the summarized score: low risk: score <-10; low–
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Fig. 1. Overall survival of patients with non-Hodgkin lymphoma depending on the score of the predictive model (chi-square = 23.9, 
df = 3, p = 0.00003), df – degrees of freedom

































Fig. 2. Overall survival of patients with non-Hodgkin lymphoma depending on the score of the predictive model <0 and ≥0 (Cox’s 
F-test, p < 0.00001)
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intermediate risk: score from –10 to –1; high risk: score from 0 to 
10; and very high risk: score >10.
In the cases with score <–10 (in 17 patients), the cumulative 
proportion of OS was 86.1% during the 12-month period and 75.1% 
over 24 months; in the case of scores ranging from –10 to –1 (in 
12 patients), it was 73.3% and 58.8%, respectively; in the case 
of scores from 0 to 10 (in eight patients), it was 38.3% and 0%, 
respectively; and in the case of scores >10 points (in eight patients), 
it was 26.0% and 4.1%, respectively (Fig. 1).
Within the group of all examined patients, 0 points can be considered 
as the threshold of prognostic model scores, because the survival 
was similar in two subgroups with score <–10 and scores ranging 
from –10 to 0 (i.e., <0), and in two subgroups with scores from 0 to 
10 and >10 (i.e., ≥0), as seen in Fig. 1. Having divided all patients 
into two groups with scores <0 (29 patients) and ≥0 (16 patients), 
the cumulative proportion of OS in the first group was 85.1% for 
12 months and 78.3% for 24 months, and in the second group, 
37.7% and 5.1%, respectively. The difference between the two 
groups was highly significant (Cox’s F-test, p < 0.00001) (Fig. 2).
Discussion
In the composition of the incidence of hematological malignancies 
in Ukraine, the incidence of mature lymphoid neoplasms was 
52.1%, including 18.6% NHL and 22.4% CLL [10]. In recent years, 
the prognosis of these diseases has improved significantly due 
to the use of modern polychemotherapy and biological agents. 
For example, more than half of patients with diffuse large B-cell 
lymphoma may have long-term disease-free survival when treated 
with CHOP and R-CHOP regimens; however, one-third of patients 
experience relapsed or refractory malignancy after standard therapy 
[1]. Prognosis in mature lymphoid neoplasms is based on the results 
of molecular genetic studies, clinical staging (International Staging 
System (ISS), Ann Arbor, Rai, and Binet), and estimation of IPI and 
its modifications for different types of NHL. However, in patients with 
identical prognostic indicators, differences in consequences of a 
disease are often found. Therefore, the prognosis is supplemented 
by a number of predictive biomarkers, and investigations are aimed 
at finding new prognostic factors that would allow determination of 
the degree of risk in each case, creating the basis for individually 
tailored therapy [2, 3]. However, recommendations regarding 
the prognostic value of some markers of systemic inflammation, 
disorders of blood coagulation, and dyslipidemia in patients with 
different types of mature lymphoid neoplasms have not yet been 
elaborated.
The microenvironment of malignancies plays an important role 
in tumor growth and metastasis because tumor cells produce 
proinflammatory cytokines, such as IL-6, IL-1A, IL-8 and others. 
Systemic inflammatory response in patients with mature lymphoid 
neoplasms is one of the causes of anemia (anemia of chronic 
disease), which was partly confirmed by the weak inverse 
correlation between levels of hemoglobin and IL-6 in our study. 
Anemia reflects an unfavorable prognosis of tumor course [11, 12]. 
Decreased hemoglobin level is taken into account for CLL staging 
by the Rai and Binet methods, as well as for prognosis in patients 
with Waldenstrom’s macroglobulinemia in International Prognostic 
Staging System for Waldenstrom's macroglobulinemia in the 
Follicular Lymphoma International Prognostic Index (FLIPI) and 
FLIPI-2. It should be noted that according to the model proposed by 
Khorana [13], anemia with hemoglobin levels <100 g/L is associated 
with an increased risk of thrombosis in patients with malignant 
tumors, including lymphomas, and development of thrombosis 
may affect prognosis [14]. Our study established that hemoglobin 
level <120 g/L is an unfavorable predictive marker in patients with 
different types of NHL.
According to the literature data, blood cytokine levels are important 
for predicting the survival of patients with hematological neoplasms, 
in particular, those with NHL [3, 4]. This is due to the influence of 
cytokines on the proliferation, differentiation, and migration of tumor 
and stromal cells, as well as on the regulation of communication 
between a tumor and its stroma, and the interaction of a tumor with 
its extracellular matrix [15]. Proinflammatory cytokines change the 
anticoagulant properties of the endothelium to procoagulant ones, 
which promotes the peritumoral formation of fibrin deposits as “a 
scaffold” for the invasive growth of malignant cells [16, 17].
It should be noted that the relationship between levels of cytokines 
and survival is studied, as a rule, in patients with concrete mature 
lymphoid neoplasms, such as diffuse large B-cell lymphoma [3]. 
We clarified the universal significance of some cytokine levels in 
predicting the course of many types of NHL. Our study revealed the 
relationship between worsening survival of patients with different 
types of NHL and systemic inflammation, reflected by the increased 
ESR and altered levels of fibrinogen, IL-6, and TNF. Dependence 
between the level of TNF-� and life expectancy was also observed 
in patients with other hematological neoplasms, in particular, 
in those with myelodysplastic syndrome [18]. According to the 
literature, TNF levels are positively associated with the degree 
of NHL malignancy [5]. Barilka et al. [12] showed that increased 
levels of TNF-� can induce the development of anemia already in 
the early stages of CLL. According to Patel and Patel [19], TNF-� 
promotes proteolysis, loss of adipose tissue, and a decrease in 
protein and lipid synthesis.
Our studies revealed that laboratory features of systemic 
inflammation are associated with hypercoagulability. Similar data 
are available in literature sources [20]. It has been established 
that hypercoagulability can be induced by malignant cells, both 
directly and indirectly through tumor-associated cytokines that 
are produced by macrophages or endothelial cells, and IL-6 is 
defined as a key regulator of paraneoplastic thrombocytosis and 
hyperfibrinogenemia [21]. The presence of IL-6 in the blood and 
levels of TNF-� >0.285 pg/mL are considered to be associated 
with the risk of venous thromboembolism [22]. In patients with 
mature lymphoid neoplasms, there are often elevated levels of 
hypercoagulability markers, such as fibrin degradation products, 
d-dimer, and tissue factor [6]. Hypercoagulability in these patients 
is associated with increased predisposition to thrombosis, which 
significantly impairs prognosis [23]. Thus, inflammation is one of 
the leading mechanisms in the development of hypercoagulability 
and thrombi, which can contribute to or lead to lethal outcomes.
The current study revealed the relationship between 
hypercoagulability and unfavorable prognosis in NHL. In patients 
with NHL without thrombotic complications, hypercoagulability 
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markers, such as increased levels of SFMCs and shortened 
APTT before the administration of chemotherapy, were significant 
predictors of worse OS. Similar results were obtained by Rubio-
Jurado et al. [6] and Bi et al. [2], who revealed that high levels 
of d-dimer before the onset of treatment for NHL correlated with 
adverse clinical features and incomplete response to treatment 
and, as such, predicted worsening of patients’ survival. According 
to the literature, hypercoagulability can directly or indirectly promote 
tumor progression and metastasis [21, 24].
It is known that dyslipidemia contributes to the development of 
atherosclerotic changes in the arteries, causing ischemic diseases 
that are among the leading causes of death in the world. Patients 
with NHL often suffer from coincident cardiovascular diseases, 
the progression of which is frequently caused by lipid metabolism 
disorders. The association of dyslipidemia with prognosis of NHL 
has not yet been studied.
According to the literature, HDL has anti-inflammatory actions, 
which are implemented on the cellular and molecular levels [25]. 
Low concentrations of HDL-Ch are associated with systemic 
inflammation, which contributes to atherogenesis and thrombosis 
[7, 26]. It has been reported that HDL has a protective effect against 
thrombosis due to inhibition of platelet activation and endothelial 
dysfunction, promotion of endothelial-dependent vasodilation, and 
reduction of thrombin generation by enhancing the anticoagulant 
properties of protein C [27]. Population studies demonstrate an 
inverse association between plasma HDL levels and the incidence 
of venous thromboembolism [28]. We confirmed the associations 
between levels of HDL-Ch and markers of inflammation and 
hypercoagulability.
The current study found that decreased level of HDL-Ch was a 
predictor of worse OS of patients with NHL. This result is in line with 
the literature data, in which low level of HDL-Ch is associated with 
the risk of death, sepsis, and malignant tumors [29].
Among the clinical functional parameters, ECOG performance 
status is used in Prognostic System IPI and Mantle Cell Lymphoma 
IPI. Our study revealed that it has a self-dependent value in NHL 
prognosis.
The revealed correlations between the studied parameters confirm 
the data in the literature about interactions among systemic 
inflammation, hypercoagulability, and dyslipidemia, which may play 
a role in the worsening of the functional ability of patients with NHL 
and their survival.
Consequently, the results of the performed study substantiate the 
use of ECOG performance status, hemoglobin concentrations, 
ESR, APTT, as well as levels of fibrinogen, SFMCs, IL-6, TNF, and 
HDL-Ch, obtained before treatment administration, as additional 
prognostic criteria for estimation of death risk in patients with 
different types of NHL. We propose to evaluate the risk of death 
within the following 1.5–2 years using these parameters together 
and calculating the summarized score.
Conclusions
In patients with NHL, markers with a negative predictive value for 
OS are the following: laboratory features of systemic inflammation 
and tumor intoxication, such as levels of fibrinogen ≥6 g/L, IL-6 
≥2 pg/mL, TNF ≥1.45 pg/mL, ESR >30 mm/h, and anemia with 
hemoglobin levels <120 g/L; hypercoagulable state with levels of 
SFMCs >4 mg/dL and short APTT; low HDL-Ch levels <1.03 mmol/L 
in men and <1.29 mmol/L in women; as well as ECOG status score 
>1. Three of the established markers are independent predictors: 
ECOG score and levels of SFMCs and IL-6. The prognostic model 
for estimation of the risk of death within the ensuing 1.5–2 years was 
thus created, which included the above-mentioned nine predictive 
markers.
Registration of clinical trials
The research was conducted in accordance with the research plan 
of the State Institution “Institute of Blood Pathology and Transfusion 
Medicine of the NAMS of Ukraine” (Lviv). It is a piece of research 
conducted by the Department of Hematology in association with 
the Laboratory Group working on the topic “Establishing a complex 
of prognostic factors for assessment of the disease course and 
stratification of treatment plans in patients with chronic lymphocytic 
leukemia” (state registration number: 0116U000176).
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